Vertex Pharmaceuticals (VRTX) Q3 2024 Earnings Call Transcript

Nov 4, 2024 · VRTX earnings call for the period ending September 30, 2024. Image source: The Motley Fool. Vertex Pharmaceuticals ( VRTX -0.03% ) Q3 2024 Earnings Call Nov 04, 2024 , …

CouponFollow Extension

03%
OFF

Vertex Pharmaceuticals (VRTX) Q3 2024 Earnings Call Transcript

3 weeks from now

Nov 4, 2024 · VRTX earnings call for the period ending September 30, 2024. Image source: The Motley Fool. Vertex Pharmaceuticals ( VRTX -0.03% ) Q3 2024 Earnings Call Nov 04, 2024 , …

fool.com

3%
OFF

VRTX | Vertex Pharmaceuticals Earnings Transcripts - StockLight

3 weeks from now

Vertex Pharmaceuticals; Earnings Transcripts Vertex Pharmaceuticals Earnings ... Transcript Closing Price August 2nd, 2024 Q2 2024 Earnings Call Transcript: $494.46 (-2.3%) May 7th, …

stocklight.com

71%
OFF

Vertex Pharmaceuticals (VRTX) Earnings Date And Reports 2025

3 weeks from now

Vertex Pharmaceuticals (VRTX) Earnings Date, Estimates & Call Transcripts $438.40-3.12 (-0.71%) Closing price 03:59 PM Eastern ... Vertex Pharmaceuticals released Q3 2024 earnings …

marketbeat.com

03%
OFF

Vertex Pharmaceuticals (VRTX) Q3 2023 Earnings Call Transcript

3 weeks from now

Nov 7, 2023 · Vertex Pharmaceuticals (VRTX-0.03%) Q3 2023 Earnings Call Nov 06, 2023, 4:30 p.m. ET. Contents: Prepared Remarks; Questions and Answers; Call Participants; Prepared …

fool.com

12%
OFF

Vertex Pharmaceuticals Inc (VRTX) Q3 2024 Earnings Call Highligh

3 weeks from now

Nov 5, 2024 · Revenue: $2.77 billion in Q3 2024, 12% growth compared to Q3 2023.Full-Year Revenue Guidance: Increased to $10.8 billion to $10.9 billion.Non-GAAP Operating In ...

gurufocus.com

$4.38
OFF

VRTX Q3 Earnings & Sales Trump Estimates, '24 Sales View Raised

3 weeks from now

Nov 5, 2024 · Vertex Pharmaceuticals Incorporated VRTX reported adjusted earnings of $4.38 per share for the third quarter of 2024, surpassing the Zacks Consensus Estimate of $4.13. In …

yahoo.com

12%
OFF

Earnings Call: Vertex Pharmaceuticals Q3 2024 Revenue Climbs 12%

3 weeks from now

Nov 5, 2024 · Full transcript - Vertex Pharmaceuticals Inc (NASDAQ: VRTX) Q3 2024: Operator: Good day. And welcome to the Vertex Pharmaceuticals Third Quarter 2024 Earnings Call. All …

investing.com

FAQs about Vertex Pharmaceuticals (VRTX) Q3 2024 Earnings Call Transcript Coupon?

How did Vertex Pharmaceuticals (VRTX) perform in Q3 2024?

Vertex Pharmaceuticals Inc (NASDAQ:VRTX) reported a 12% year-over-year revenue growth for Q3 2024, reaching $2.77 billion. The company increased its full-year product revenue guidance to $10.8 billion to $10.9 billion, reflecting strong growth and performance. ...

How much will Vertex Pharmaceuticals earn in 2024?

Earnings for Vertex Pharmaceuticals are expected to grow by 4.40% in the coming year, from $15.22 to $15.89 per share. Vertex Pharmaceuticals has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, August 6th, 2024 based off prior year's report dates. ...

When is Vertex Pharmaceuticals' next earnings release date?

Vertex Pharmaceuticals has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, August 6th, 2024 based off last year's report dates. Learn more on VRTX's earnings history. Did Vertex Pharmaceuticals beat their earnings estimates last quarter? ...

How much cash does Vertex Pharmaceuticals have?

According to the 10-Q SEC Filing, Vertex Pharmaceuticals had cash, cash equivalents and marketable securities of $6.52 billion as of September 30th of 2024. The company lays out in this SEC Filing that it believes it only has enough cash on hand to fund its operations for at least the next 12 months. ...

When is Vertex Pharmaceuticals' primary completion date?

Plus, the fact that the clinicaltrials website I linked at the beginning of this paragraph above denotes that the estimated primary completion date is slated for March of 2025. According to the 10-Q SEC Filing, Vertex Pharmaceuticals had cash, cash equivalents and marketable securities of $6.52 billion as of September 30th of 2024. ...

Does vertex have a market opportunity for journavx?

Before going over the particular study that allowed Vertex to receive U.S. marketing approval of JOURNAVX, it is first to go over what acute pain is and what the possible market opportunity could be. Acute pain is characterized as a sudden onset of pain experienced by a patient due to a trauma or injury. ...